Long-term effects of weight-reducing drugs in hypertensive patients

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 3, 2013, Pages

  Siebenhofer, Andrea ^a   Jeitler, Klaus ^b   Horvath, Karl ^b   Berghold, Andrea ^b   Siering, Ulrich ^c   Semlitsch, Thomas ^b  

^a GOETHE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALL CAUSE MORTALITY; BLOOD PRESSURE REGULATION; BODY WEIGHT CHANGE; BODY WEIGHT LOSS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; MENTAL DISEASE; META ANALYSIS; MORBIDITY; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; XEROSTOMIA; ADULT; BLOOD PRESSURE; DRUG RECALL; FEMALE; LOW CALORY DIET; MALE; MIDDLE AGED; MORTALITY; TIME; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; BLOOD PRESSURE; CYCLOBUTANES; DIET, REDUCING; FEMALE; HUMANS; HYPERTENSION; LACTONES; MALE; MIDDLE AGED; PIPERIDINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY-BASED DRUG WITHDRAWALS; TIME; WEIGHT LOSS;

MLCS; MLOWN;

EID: 84880082325     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007654.pub3     Document Type: Review

References (102)

1. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Journal of Hypertension 2002;20(11):2257-67.
2. Cocco G, Pandolfi S, Rousson V. Sufficient weight reduction decreases cardiovascular complications in diabetic patients with the metabolic syndrome: A randomized study of orlistat as an adjunct to lifestyle changes (diet and exercise). HeartDrug 2005;5(2):68-74.
3. Fanghaenel G, Cortinas L, Sanchez-Reyes L, Gomez-Santos R, Campos-Franco E, Berber A. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Advances in Therapy 2003;20(2):101-13.
4. Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea F, Sr, Zanella MT. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes, Obesity & Metabolism 2005;7(3):246-53.
5. Faria AN, Ribeiro Filho FF, Lerario DDG, Kohlmann N, Gouvea Ferreira SR, Zanella MT. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. Portuguese, English]. Arquivos Brasileiros de Cardiologia 2002;78(2):172-80.
6. Guy-Grand B, Drouin P, Eschwege E, Gin H, Joubert JM, Valensi P. Effects of orlistat on obesity-related diseases - a six-month randomized trial. Diabetes, Obesity & Metabolism 2004;6(5):375-83.
7. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Archives of Internal Medicine 2000;160(14):2185-91.
8. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Journal of Human Hypertension 2002;16(1):5-11.
9. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension [Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: A-Gewichtsreduktion]. http://iqwig.de/download/A05-21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck_neu.pdf. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2006:19-119.
10. Torgerson JS, Arlinger K, Kappi M, Sjostrom L. Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. Controlled Clinical Trials 2001;22(5):515-25.
11. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes care 2004;27(1):155-61.
12. Bach DS, Rissanen AM, Mendel CM, Shepherd G, Weinstein SP, Kelly F, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obesity Research 1999;7(4):363-9.
13. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obesity Research 1999;7(2):189-98.
14. Broom I, Wilding J, Stott P, Myers N, UK Multimorbidity Study Group. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. International Journal of Clinical Practice 2002;56(7):494-9.
15. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.see comment]erratum appears in JAMA 1999 Apr 7;281(13):1174]. JAMA 1999;281(3):235-42.
16. de Castro J J, Dias T, Chambel P, Carvalheiro M, Correia L G, Guerreiro L, et al. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia. Rev Port Cardiol 2009;28(12):1361-74.
17. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clinical Therapeutics 2003;25(4):1107-22.
18. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, et al. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism: Clinical & Experimental 2008;57(11):1552-7.
19. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, et al. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. J Pharm Pharm Sci 2010;13(3):378-90.
20. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, et al. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. J Clin Pharm Ther 2011;36(5):592-601.
21. Despres J-P, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 2005;353(20):2121-34.
22. Despres J P, Ross R, Boka G, Almeras N, Lemieux I. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29(3):416-23.
23. Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebocontrolled study in 322 overweight and obese patients with dyslipidemia. American heart journal 2001;142(3):489-97.
24. Erdmann J, Lippl F, Klose G, Schusdziarra V. Cholesterol lowering effect of dietary weight loss and orlistat treatment - Efficacy and limitations. Alimentary Pharmacology and Therapeutics 2004;19(11):1173-9.
25. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2000;24(2):144-50.
26. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2001;25(5):741-7.
27. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2000;24(3):306-13.
28. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2000;2(3):175-87.
29. Gentile S, Guarina G, Padovano B, Buonocunto F, Gruppo Campano Obesita. Efficacy and safety of a short-time orlistat treatment in obese subjects]. Italian]. Annali Italiani di Medicina Interna 2005;20(2):90-6.
30. Ginsberg DL. Add-on sibutramine for olanzapine-induced weight gain. Primary Psychiatry 2004;11(7):24.
31. Halpern A, Leite CC, Herszkowicz N, Barbato A, Costa AP. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study. Revista do Hospital das Clinicas; Faculdade de Medicina Da Universidade de Sao Paulo 2002;57(3):98-102.
32. Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes, Obesity & Metabolism 2003;5(3):180-8.
33. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study Group, et al. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Experimental & Clinical Endocrinology & Diabetes 2004;112(4):201-7.
34. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings.see comment]. Archives of Family Medicine 2000;9(2):160-7.
35. Heinonen M V, Laaksonen D E, Karhu T, Karhunen L, Laitinen T, Kainulainen S, et al. Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2009;19(9):626-33.
36. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. American Journal of Medicine 2007;120(2 Suppl 1):S18-28.
37. Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, et al. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. Diabetic Medicine 2005;22(8):1024-30.
38. Jain S S, Ramanand S J, Ramanand J B, Akat P B, Patwardhan M H, Joshi S R. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab 2011;15(2):99-104.
39. James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 1997;21 Suppl 3:S24-30, 1997 Jun.:-30.
40. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.see comment]. Lancet 2000;356(9248):2119-25.
41. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2004;28(4):600-5.
42. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.erratum appears in Diabetes Care. 2003 Mar;26(3):971.]. Diabetes Care 2002;25(6):1033-41.
43. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.see comment]. Journal of Internal Medicine 2000;248(3):245-54.
44. Lindgarde F. Orlistat with diet was effective and safe for weight loss and coronary risk reduction in obesity. Evidence-Based Medicine 2001;6(2):54.
45. Lindgarde F. Effect of orlistat on coronary heart disease risk in obese patients with hypertension and/or hyperlipidemia. Am Heart J 2001;141(1):171.
46. Madsen E L, Bruun J M, Skogstrand K, Hougaard D M, Christiansen T, Richelsen B. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metabolism 2009;58(7):946-53.
47. McNulty SJ, Ur E, Williams G, Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26(1):125-31.
48. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.erratum appears in Diabetes Care. 2002 Sep;25(9):1671.]. Diabetes Care 2002;25(7):1123-8.
49. Nissen S E, Nicholls S J, Wolski K, Rodes-Cabau J, Cannon C P, Deanfield J E, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299(13):1547-60.
50. O'Leary D H, Reuwer A Q, Nissen S E, Despres J P, Deanfield J E, Brown M W, et al. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart 2011;97(14):1143-50.
51. Pathan MF, Latif ZA, Nazneen NE, Mili SU. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. Bangladesh Medical Research Council Bulletin 2004;30(1):1-8.
52. Patschan S, Scholze J. Obesity-related hypertension. Cardiology Review 2007;24(12):32-5.
53. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.see comment]erratum appears in JAMA. 2006 Mar 15;295(11):1252]. JAMA 2006;295(7):761-75.
54. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. American Journal of Cardiology 2001;87(7):827-31.
55. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obesity Research 2000;8(1):49-61.
56. Rossner S. Sibutramine--antidepressive agent tested against obesity. [Swedish]. Lakartidningen 2001;98(15):1802-3.
57. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes, Obesity and Metabolism 2003;5(3):195-201.
58. Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: Overview of clinical trials with sibutramine and orlistat. Diabetes and Metabolism 2002;28(6 I):437-45.
59. James P, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, et al. Effects on mortality and morbidity in overweight/obese subjects: The sibutramine cardiovascular outcomes (SCOUT) trial. Journal of the American College of Cardiology 2010;Conference: American College of Cardiology's 59th Annual Scientific Session and i2 Summit: Innovation in Intervention Atlanta, GA United States. Conference Start: 20100314 Conference End: 20100316. Conference Publication:(var.pagings). 55 (10 SUPPL 1):A141.E1326.
60. James W P, Caterson I D, Coutinho W, Finer N, Van Gaal L F, Maggioni A P, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363(10):905-17.
61. James W Philip T. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. European Heart Journal Supplements 2005;7(suppl_L):L44-48.
62. Maggioni A P, Caterson I, Coutinho W, Finer N, Gaal L V, Sharma A M, et al. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. J Cardiovasc Pharmacol 2008;52(5):393-402.
63. Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, et al. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes, obesity & metabolism 2009;11(3):239-50. [PUBMED: 18671798]
64. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.see comment]. Lancet 1998;352(9123):167-72.
65. Suyog J, Milind P, Karuna R. Comparison of efficacy and safety of rimonabant with orlistat in obese and overweight patients. International Journal of Pharma and Bio Sciences 2011;2(1):179-87.
66. Svendsen M, Rissanen A, Richelsen B, Rossner S, Hansson F, Tonstad S. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial. Obesity (Silver Spring) 2008;16(2):327-33.
67. Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes, Obesity & Metabolism 2005;7(3):254-62.
68. Tambascia MA, Geloneze B, Repetto EM, Geloneze SR, Picolo M, Magro DO. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes, Obesity & Metabolism 2003;5(5):338-44.
69. Tiikkainen M, Bergholm R, Rissanen A, Aro A, Salminen I, Tamminen M, et al. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. American Journal of Clinical Nutrition 2004;79(1):22-30.
70. Triay J, Mundi M, Klein S, Toledo F G, Smith S R, Abu-Lebdeh H, et al. Does rimonabant independently affect free fatty acid and glucose metabolism?. J Clin Endocrinol Metab 2012;97(3):819-27.
71. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.see comment]erratum appears in Lancet. 2005 Jul 30-Aug 5;366(9483):370]. Lancet 2005;365(9468):1389-97.
72. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O, et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. European Heart Journal 2008;29(14):1761-71.
73. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial.see comment]. JAMA 2001;286(11):1331-9.
74. Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. American heart journal 2002;144(3):508-15.
75. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. Journal of Hypertension 1998;16(12 Pt 2):2013-7.
76. Abbott Germany. Theobald F. Press release: [Abbott setzt Vertrieb seiner Medikamente mit dem Wirkstoff Sibutramin zur Behandlung von Adipositas in den Ländern der Europäischen Union aus.] 2010 [cited 2013 Jan 14]. Available from: http://www.abbott.de/press/show/e7340/e19695/e18095/Sibutramin_210110_Theobald_de.pdf.
77. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005;45(6):1035-41. [PUBMED: 15897373]
78. Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2012;28(3):270-87.
79. The Cochrane Collaboration. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated 2011 March; cited 2013 Jan 14]. Available from: http://handbook.cochrane.org/. Chichester, UK: John Wiley & Sons, Ltd.
80. Topol E J, Bousser M G, Fox K A, Creager M A, Despres J P, Easton J D, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010;376(9740):517-23. [PUBMED: 20709233]
81. Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes, obesity & metabolism 2005;7(1):47-55. [PUBMED: 15642075]
82. European Medicines Agency (EMA). Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) [updated 2008 Oct 23; cited 2012 Dec 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014779.pdf. European Medicines Agency, Post-authorisation Evaluation of Medicines for Human Use.
83. European Medicines Agency (EMA). Press Release - The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia [updated 2008 Oct 23; cited 2012 Dec 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500014774.pdf. European Medicines Agency, Press office.
84. European Medicines Agency (EMA). Public Statement on Acomplia (rimonabant) - Withdrawal of the marketing authorisation in the European Union [updated 2009 Jan 30; cited 2012 Dec 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012189.pdf. European Medicines Agency, Post-authorisation Evaluation of Medicines for Human Use.
85. European Medicines Agency (EMA). Press Release - European Medicines Agency recommends suspension of marketing authorisations for sibutramine [updated 2010 Jan 21; cited 2012 Dec 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500069995.pdf 2010.
86. European Medicines Agency (EMA). Questions and answers on the suspension of medicines containing sibutramine [updated 2010 Aug 06; cited 2012 Dec 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sibutramine_107/WC500094238.pdf 2010.
87. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87. [PUBMED: 17563527]
88. Food, Drug Administration. Egan AG. Colman EG. FDA Rimonabant Briefing Document. Endocrine and Metabolic Drugs Advisory Committee. 2007 [updated 2007 Jun 13; cited 2012 Dec 18]. Available from: http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4306b1-fda-backgrounder.pdf. Food and Drug Administration, Endocrine and Metabolic Drugs Advisory Committee.
89. US Food, Drug Administration (FDA). Recommendation on a regulatory decision for Meridia (sibutramine) [updated 2010 Oct 07; cited 2012 Dec 18]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM228795.pdf 2010.
90. US Food, Drug Administration (FDA). FDA News Release: Abbott Laboratories agrees to withdraw its obesity drug Meridia [updated 2010 Oct 08; cited 2012 Dec 18]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm228812.htm 2010.
91. Horvath K, Jeitler K, Siering U, Stich AK, Skipka G, Gratzer TW, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Archives of internal medicine 2008;168(6):571-80. [PUBMED: 18362248]
92. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension [Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: A-Gewichtsreduktion]. Available from: http://iqwig.de/download/A05-21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck_neu.pdf. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2006:19-119.
93. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72. [PUBMED: 12748199]
94. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obesity Research 2003;11(9):1116-23. [PUBMED: 12972682]
95. National Institute for Health and Clinical Excellence. Hypertension - The clinical management of primary hypertension in adults; Clinical Guideline 127. 2011 [updated 2011 Aug; cited 2012 Dec 18]. Available from: http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf. Newcastle: National Institute for Health and Clinical Excellence.
96. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369(9555):71-7. [PUBMED: 17208644]
97. Moher D, Liberati A, Tetzlaff J, Altman D G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264-9, W64. [PUBMED: 19622511]
98. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335(7631):1194-9. [PUBMED: 18006966]
99. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368(9548):1660-72. [PUBMED: 17098084]
100. Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich A K, Matyas E, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007654.pub2; PUBMED: 19588440]
101. World Health Organization [homepage on the internet]. Khatib OMN, El-Guindy MS, editors. Clinical guidelines for the management of hypertension. WHO EMRO Technical publication series, 29. 2005 [cited 2013 Jan 14]. Regional Office for the Eastern Mediterranean. Available from: http://www.emro.who.int/dsaf/dsa234.pdf. Cairo: World Health Organization. Regional Office for the Eastern Mediterranean.
102. World Health Organization [homepage on the Internet]. Fact Sheet 317 - Cardiovascular diseases (CVDs) 2011 [cited 2012 Dec 18]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. WHO.